Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox(®)), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refractory acute promyelocytic leukaemia (APL). Kleijnen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Ramaekers, Bram L. T., Riemsma, Rob, Grimm, Sabine, Fayter, Debra, Deshpande, Sohan, Armstrong, Nigel, Witlox, Willem, Pouwels, Xavier, Duffy, Steven, Worthy, Gill, Kleijnen, Jos, Joore, Manuela A.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2018
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6559128/
https://ncbi.nlm.nih.gov/pubmed/30426463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0738-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars